Prognosis and predictive factors in prostate cancer;Facteurs pronostiques et prédictifs du cancer de la prostate

Bulletin du Cancer

Volumn 96, Issue 4, 2009, Pages 439-449

  Albiges Sauvin, L ^a   Levy A ^a   Massard, C ^a   Fizazi, K ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Angiogenesis; Circulating tumor cell; Predictive factor; Prognosis factors; Prostate cancer

Indexed keywords

DOCETAXEL; PROTEIN;

ANGIOGENESIS; CANCER CELL; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURGERY; CASTRATION; CELL INVASION; CLINICAL ASSESSMENT; GANGLION; HUMAN; HYPOXIA; METASTASIS; MICROARRAY ANALYSIS; MICROENVIRONMENT; NONHUMAN; PREOPERATIVE EVALUATION; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RISK ASSESSMENT; SURGICAL RISK; TUMOR BIOPSY;

BONE NEOPLASMS; HUMANS; MALE; MICROARRAY ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SEMINAL VESICLES;

EID: 66349105413     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.0846     Document Type: Review

References (57)

1. Rebillard X, Tretarre B. groupe FRANCIM: epidemiology of urological cancer in France. Rev Prat 2007 ; 57 : 595-602. (Pubitemid 46639888)
2. Remontet L, Estève J, Bouvier AM, Grosclaude P, Launoy G, Menegoz F, et al. Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique 2003 ; 51 : 3-30.
3. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997 ; 227 : 1445-1451
4. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998 ; 90 : 766-771 (Pubitemid 28259189)
5. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998 ; 280 : 969-974 (Pubitemid 28445094)
6. Eastham JA, May R, Robertson JL, Sartor O, Kattan MW. Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL. Urology 1999 ; 54 : 709-713 (Pubitemid 29449435)
7. Karakiewicz PI, Benayoun S, Kattan MW, Perrotte P, Valiquette L, Scardino PT, et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol 2005 ; 173 : 1930-1934 (Pubitemid 40675214)
8. Chun FK, Briganti A, Graefen M, Montorsi F, Porter C, Scattoni V, et al. Development and external validation of an extended 10-core biopsy nomogram. Eur Urol 2007 ; 52 : 436-444 (Pubitemid 46963425)
9. Chun FK, Briganti A, Graefen M, Porter C, Montorsi F, Haese A, et al. Development and external validation of an extended repeat biopsy nomogram. J Urol 2007 ; 177 : 510-515 (Pubitemid 46054043)
10. Lopez-Corona E, Ohori M, Scardino PT, Reuter VE, Gonen M, Kattan MW. A nomogram for predicting a positive repeat prostate biopsy in patients with a negative biopsy session. J Urol 2003 ; 170 : 1184-1188 (Pubitemid 37108108)
11. Walz J, Graefen M, Chun FK, Erbersdobler A, Haese A, Steuber T, et al. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 2006 ; 50 : 498-505. (Pubitemid 44189057)
12. Bhojani N, Salomon L, Capitanio U, Suardi N, Shariat SF, Jeldres C, et al. External validation of the updated partin tables in a cohort of French and Italian men. Int J Radiat Oncol Biol Phys 2009 ; 73 : 347-352
13. Penson DF, Grossfeld GD, Li YP, Henning JM, Lubeck DP, Carroll PR. How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor. J Urol 2002 ; 167 : 1653-1657 (discussion 1657-8). (Pubitemid 34240692)
14. Steuber T, Graefen M, Haese A, Erbersdobler A, Chun FK, Schlom T, et al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol 2006 ; 175 : 939-944 (Pubitemid 43200025)
15. Ohori M, Kattan MW, Koh H, Maru N, Slawin KM, Shariat S, et al. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 2004 ; 171 : 1844-1849 (Pubitemid 38501019)
16. Koh H, Kattan MW, Scardino PT, Suyama K, Maru N, Slawin K, et al. A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results. J Urol 2003 ; 170 : 1203-1208 (Pubitemid 37108113)
17. Gallina A, Chun FK, Briganti A, Shariat SF, Montorsi F, Salonia A, et al. Development and split-sample validation of a nomogram predicting the probability of seminal invasion at radical prostatectomy. Eur Urol 2007 ; 52 : 98-105. (Pubitemid 46803017)
18. Briganti A, Chun FK, Salonia A, Gallina A, Farina E, Da Pozzo LF, et al. Validation of a nomogram predicting the probability of lymph node invasion based on the extend of pelvic lymphadenectomy in patient with clinically localized prostate cancer. BJU Int 2006 ; 98 : 788-793 (Pubitemid 44368026)
19. Vira MA, Guzzo T, Heitjan DF, Tomaszewski JE, D'Amico A, Wein AJ, et al. Is the biopsy Gleason score important in predicting outcomes for patients after radical prostatectomy once the pathological Gleason score is known? BJU Int 2008 ; 101 : 1232-1236
20. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004 ; 351 : 125-135 (Pubitemid 38886647)
21. Graefen M, Karakiewicz PI, Cagiannos I, Quinn DI, Henshall SM, Grygiel JJ, et al. International validation of preoperative nomogram for prostate cancer recurrence following radical prostatectomy. J Clin Oncol 2002 ; 20 : 3206-3212 (Pubitemid 34831516)
22. D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Kaplan I, et al. Pretreatment nomogram for prostate specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999 ; 17 : 168-172 (Pubitemid 29022390)
23. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Fondurulia J, Chen MH, et al. Clinical utility of the pourcentage of positive prostate biopsies in defining bio chemical outcome after radical prostectomy for for clinically localized prostate cancer. J Clin Oncol 2000 ; 18 : 1164-1172 (Pubitemid 30159832)
24. Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000 ; 18 : 3352-3359
25. Kattan MW, Zelefsky MJ, Kupelian PA, Cho D, Scardino PT, Fuks Z, et al. Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol 2003 ; 21 : 4568-4571 (Pubitemid 46594028)
26. Pisansky TM, Kahn MJ, Bostwick DG. An enhanced prognostic system for clinically localized carcinoma of the prostate. Cancer 1997 ; 79 : 2154-2161 (Pubitemid 27227380)
27. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999 ; 17 : 1499-1507 (Pubitemid 29220858)
28. Stephenson AJ, Scardino PT, Eastham JA, Bianco Jr. FJ, Dotan ZA, DiBlasio CJ, et al. Postoperative nomogram predicting the 10- year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005 ; 23 : 7005-7012 (Pubitemid 46260287)
29. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to allcause mortality. J Clin Oncol 2007 ; 25 : 1765-1771 (Pubitemid 46797959)
30. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005 ; 294 : 433-439 (Pubitemid 41124175)
31. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007 ; 25 : 2035-2041 (Pubitemid 46972788)
32. Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 2003 ; 169 : 164-169 (Pubitemid 35461578)
33. Kwak C, Jeong SJ, Park MS, Lee E, Lee SE. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 2002 ; 168 : 995-1000.
34. Millikan RE, Wen S, Pagliaro LC, Brown MA, Moomey B, Do KA, et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 2008 ; 26 : 5936-5942
35. Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventós CX, et al. Usefulness of prostate specific antigen nadir as predictor of androgen - independant progression of metastatic prostate cancer. Int J Biol Markers 2005 ; 20 : 209-216 (Pubitemid 43103616)
36. Brasso K, Christensen IJ, Johansen JS, Teisner B, Garnero P, Price PA, et al. Pronostic value of PNIP, bone alkaline phosphatase, CTX- 1 and YKL-40 in patients with metastatic prostate carcinoma. Prostate 2006 ; 66 : 503-513
37. Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002 ; 20 : 3972-3982
38. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007 ; 13 : 6396-6403 (Pubitemid 350075029)
39. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara Jr. PN, et al. Evaluation of prostate specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006 ; 98 : 516-521 (Pubitemid 43898814)
40. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Carducci MA, Tannock I, de Wit R, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007 ; 25 : 3965-3970 (Pubitemid 47477275)
41. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar- Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression in prostate cancer. Nature 2002 ; 419 (6907) : 624-629
42. Rubin MA, Bismar TA, Andrén O, Mucci L, Kim R, Shen R, et al. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 2005 ; 14 : 1424-1432 (Pubitemid 40807341)
43. Cooper CS, Campbell C, Jhavar S. Mechanisms of disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer. Nat Clin Pract Urol 2007 ; 4 : 677-687 (Pubitemid 350238074)
44. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004 ; 113 : 913-923 (Pubitemid 38544150)
45. Stephenson AJ, Smith A, Kattan MW, Satagopan J, Reuter VE, Scardino PT, et al. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer 2005 ; 104 : 290-298 (Pubitemid 40993255)
46. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, et al. Gene expression alterations in prostate cancer predicting tumor aggresion and preceding development of maligancy. J Clin Oncol 2004 ; 22 : 2790-2799 (Pubitemid 41079896)
47. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005 ; 310 (5748) : 644-648 (Pubitemid 41528150)
48. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008 ; 8 : 497-511.
49. De Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, et al. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I-receptor. Clin Cancer Res 2007 ; 13 : 3611-3616 (Pubitemid 46955123)
50. Olmos D, Arkenau HT, Ang JE, Ledaki I, Attard G, Carden CP, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a singlecentre experience. Ann Oncol 2008 [Epub ahead of print].
51. Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, et al. Intrinsic markers of tumor hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 2008 ; 9 : 342-351
52. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006 ; 12 (20 Pt 2) : 6243s-6249s (Review). (Pubitemid 44703797)
53. Logothetis CJ, Navone NM, Lin SH. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res 2008 ; 14 : 1599-1602 (Review).
54. Coleman RE. Risks and benefits of bisphosphonates. Br J Cancer 2008 ; 98 : 1736-1740 (Review. Epub 2008 May 27).
55. Vessella RL, Corey E. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin Cancer Res 2006 ; 12 (20 Pt 2) : 6285s-6290s (Review). (Pubitemid 44703804)
56. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer 2000 ; 88 (12 Suppl) : 2919-2926 (Review). (Pubitemid 30413174)
57. Rajpar S, Laplanche A, Tournay E, Massard C, Gross-Goupil M, Fizazi K. Prognostic value of urinary N-telopeptide (uNTx) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases. J Clin Oncol 2008 ; 26 (May 20 suppl; abstr 5138).